The Feasibility Study of Docetaxel in Patients with Anaplastic Thyroid Cancer

被引：41

作者：

Kawada, Kenji ^{[1
,2
]}

Kitagawa, Koichi ^{[2
]}

Kamei, Sachi ^{[2
]}

Nada, Megumi ^{[2
]}

Mitsuma, Ayako ^{[2
]}

Sawaki, Masataka ^{[2
]}

Kikumori, Toyone ^{[3
]}

Fujimoto, Yasushi ^{[4
]}

Arima, Hiroshi ^{[5
]}

Imai, Tsuneo ^{[3
]}

Ando, Yuichi ^{[2
]}

机构：

[1] Japanese Red Cross Nagoya First Hosp, Dept Med Oncol, Nakamura Ku, Nagoya, Aichi 4538511, Japan

[2] Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, Nagoya, Aichi 4538511, Japan

[3] Nagoya Univ Hosp, Dept Breast & Endocrine Surg, Nagoya, Aichi 4538511, Japan

[4] Nagoya Univ Hosp, Dept Otorhinolaryngol, Nagoya, Aichi 4538511, Japan

[5] Nagoya Univ Hosp, Dept Endocrinol & Diabet, Nagoya, Aichi 4538511, Japan

来源：

JAPANESE JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 40卷 / 06期

关键词：

anaplastic thyroid cancer; docetaxel; chemotherapy; DOXORUBICIN PLUS CISPLATIN; RADIATION-THERAPY; CARCINOMA; TRIAL; CHEMOTHERAPY; COMBINATION;

D O I：

10.1093/jjco/hyq025

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

There is no established chemotherapy for anaplastic thyroid cancer. We conducted a prospective feasibility study at a single center to explore the antitumor activity of docetaxel against anaplastic thyroid cancer. Docetaxel was administered intravenously at a dose of 60 mg/m(2) over the course of 1 h every 3 weeks in patients with anaplastic thyroid cancer who had received no prior chemotherapy. A total of seven patients with anaplastic thyroid cancer were enrolled over the course of 30 months and received docetaxel. The treatment response was complete response in one patient, stable disease in two and progressive disease in four. The response rate was 14%, and the disease control rate (complete response plus stable disease) was 43%. The median time to progression was 6 weeks (range, 1-50). Toxicity was tolerable. Docetaxel could be an effective drug for the treatment of anaplastic thyroid cancer, with tolerable toxicity.

引用

页码：596 / 599

页数：4

共 15 条

[1] CHEMOTHERAPY OF THYROID-CARCINOMA [J].

AHUJA, S ;

ERNST, H .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1987, 10 (03) :303-310

[2] Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion [J].

Ain, KB ;

Egorin, MJ ;

DeSimone, PA .

THYROID, 2000, 10 (07) :587-594

[3]

Asakawa H, 1997, ANTICANCER RES, V17, P2757

[4] COMBINED CHEMOTHERAPY WITH BLEOMYCIN, ADRIAMYCIN, AND PLATINUM IN ADVANCED THYROID-CANCER [J].

DEBESI, P ;

BUSNARDO, B ;

TOSO, S ;

GIRELLI, ME ;

NACAMULLI, D ;

SIMIONI, N ;

CASARA, D ;

ZORAT, P ;

FIORENTINO, MV .

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1991, 14 (06) :475-480

[5]

HUNDAHL SA, 1998, CANCER, V83, P2683

[6]

KIM JH, 1987, CANCER-AM CANCER SOC, V60, P2372, DOI 10.1002/1097-0142(19871115)60:10<2372::AID-CNCR2820601004>3.0.CO

[7]

2-1

[8] Immediate causes of death in thyroid carcinoma: Clinicopathological analysis of 161 fatal cases [J].

Kitamura, Y ;

Shimizu, K ;

Nagahama, M ;

Sugino, K ;

Ozaki, O ;

Mimura, T ;

Ito, K ;

Tanaka, S .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (11) :4043-4049

[9]

Kurukahvecioglu Osman, 2007, Endocr Regul, V41, P41

[10] ANAPLASTIC CARCINOMA OF THE THYROID-GLAND TREATED BY RADIATION-THERAPY [J].

LEVENDAG, PC ;

DEPORRE, PMZR ;

VANPUTTEN, WLJ .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 26 (01) :125-128

← 1 2 →